IngredientsAccepted scientific name: Gentianopsis barbata (Froel.) Ma. This name is the accepted name of a species in the genus Gentianopsis, family Gentianaceae. The species was formally described in its current combination by the Chinese botanist Ma Yü-Chuan (Ma Y.-C.) in 1951, when he established Gentianopsis as a new genus of Chinese Gentianaceae, published in Acta Phytotaxonomica Sinica 1(1): 5–19. Gentianopsis barbata is the type species of the genus Gentianopsis.
Synonyms: The species carries several historic synonyms reflecting its earlier placement in the genus Gentiana. These include Gentiana barbata Froel. (the original basionym, published 1796 by J.A. Frölich), as well as Gentianella barbata (Froel.) Bercht. & J.Presl and Anthopogon barbatus (Froel.) Raf.
Common names: Gentianopsis barbata is commonly known as Barbed Gentian. In Chinese it is known as 扁蕾 (biǎn léi), and in Mongolian traditional medicine literature it appears under local nomenclature within the broader category of gentian medicines.
Infraspecific taxa: The species comprises several recognised infraspecific taxa, including Gentianopsis barbata subsp. barbata, Gentianopsis barbata subsp. raupii (A.E. Porsild) Elven (Raup's fringed gentian), Gentianopsis barbata var. alboflavida T.N.Ho, and Gentianopsis barbata var. stenocalyx H.W.Li ex T.N.Ho.
Family placement: The species belongs to the family Gentianaceae, tribe Gentianeae, subtribe Swertiinae, genus Gentianopsis.
The native range of Gentianopsis barbata extends from Eastern Europe to Northern Korea and the Himalaya. It is an annual or biennial and grows primarily in the temperate biome. Distribution records encompass Afghanistan, Altay, Amur, Buryatiya, China North-Central, China South-Central, Chita, East European Russia, Inner Mongolia, Irkutsk, Kamchatka, Kazakhstan, Khabarovsk, Kyrgyzstan, Korea, Krasnoyarsk, Magadan, Manchuria, Mongolia, Nepal, North European Russia, Pakistan, Qinghai, Tajikistan, Tibet, Tuva, Uzbekistan, West Himalaya, West Siberia, Xinjiang, and Yakutiya.
Morphology: Gentianopsis barbata is an annual or biennial herb 8–40 cm tall, with erect, subterete, striate stems that branch apically. Basal leaves are short petiolate, with a spatulate to oblanceolate blade 7–10 × 4–10 mm, narrowed at the base and obtuse at the apex. Stem leaves occur in 3–10 pairs and are sessile, linear to narrowly lanceolate. The corolla is tubular-funnelform, 2.5–5 cm, with elliptic lobes that are short laciniate-fringed basally, and rounded, denticulate at the apex — a feature that gives the plant its common epithet "barbed."
Gentianopsis barbata is documented as a significant medicinal plant in traditional Mongolian medicine (TMM). Gentianopsis barbata represents a significant plant species with considerable ornamental and medicinal value in China and in Mongolian medical practice. Traditional Mongolian materia medica (TMMM), as the primary substance for treatments in traditional Mongolian medicine, has long been considered an important source for drug discovery. Mongolian medicine was influenced by Ayurveda and Tibetan medical systems. Mongolians have used herbal remedies traditionally to prevent and cure diseases of humans and animals from ancient times, with about 72% of traditional Mongolian remedies developed from plants.
Within the TMM framework, G. barbata has been applied primarily to liver and biliary conditions. In traditional Mongolian medical use, G. barbata is described as improving liver tissue and cell function, preventing liver toxicity, detoxifying the body, eliminating jaundice, and removing yellowing of the skin and eyes.
For 2000 years, Gentiana and related genera such as Gentianopsis have been used widely in traditional Chinese medicine. The aerial parts of G. barbata (the whole dried herb) are the primary plant part used in both TCM and Mongolian practice, typically prepared as decoctions (water-based preparations) or dried and powdered for further processing into granules or extracts. The plant's use as a bitter agent reflects a wider pattern in the genus: some Gentiana species have been used by the nomadic people of Siberia as bitter teas or appetizers to eliminate digestive disorders such as dyspepsia, heartburn, and nausea.
Species from the Gentianeae tribe are widely used in traditional Tibetan medicine. Approximately 83 species from Gentianeae were used in Tibetan medicine, among which Gentiana and Swertia constituted the largest number of species. The species from Gentianeae are mainly used as Bangjian, Jieji, Dida, and Ganggaqiong in Tibetan medicine, each with different clinical applications. More than 240 formulas were found containing Gentianeae species with different attending functions. The broader Gentianaceae family, particularly the tribe Gentianeae to which G. barbata belongs, is used in Tibetan contexts for treating fevers, liver diseases, respiratory tract complaints, and digestive disorders, traditions consistent with the documented uses of G. barbata specifically.
Traditional preparations of G. barbata include aqueous decoctions of the whole dried herb, administration of the whole plant as a bitter tonic, and, in more refined Mongolian pharmacopoeia practice, dry extracts formulated into granules. The Russian pharmacological literature specifically references "granules of the dry extract obtained from Gentianopsis barbata (Froel.) Ma" as a formulation studied for hepatoprotective activity. The genus Gentiana is reported to be used traditionally in respiratory tract infections, gastrointestinal problems, and dermatological problems, with varied preparation methods including decoction, paste, and raw forms.
Phytochemical studies have shown that the main active components of Gentianeae species are iridoids, xanthones, flavonoids, and triterpenoids. Gentianopsis barbata shares these phytochemical classes, and specific compounds have been isolated and characterised directly from the species.
Xanthones are a chemotaxonomically diagnostic compound class in Gentianopsis. Chemotaxonomic analysis examining leaves and flowers of 13 species including the type species Gentianopsis barbata found that isoscoparin, primeverose, and 1,3,7- and 1,3,7,8-O-substituted xanthones were present in all species. Specific xanthones identified directly from G. barbata in the choleretic study by Nikolaev et al. (2003) include decussatin [1-(OH)-3,7,8-(OCH₃)₃], gentiacaulein [1,7-(OH)-3,8-(OCH₃)₂], and the xanthone glycoside gentiabavaroside [1-O-primverosyl-7-(OH)-3,8-(OCH₃)₂].
The iridoid gentiopicroside and the secoiridoid swertiamarin are among the most prominent compounds isolated from G. barbata. Compounds isolated from Gentianopsis barbata include gentiopicroside (Li et al., 2003) and swertiamarin (Wang et al., 2005). These secoiridoids are characteristic of the Gentianaceae family and are responsible for the intense bitterness of the plant. The hepatoprotective activities in Gentiana species are related to sweroside, swertiamarin, and gentiopicrin — constituents of Gentiana root. Gentian's primary therapeutic effects are linked to its ability to stimulate the production of gastric juices, digestive enzymes, and bile. Some studies revealed that gentiopicroside manifested prokinetic activity in rats with gastrointestinal motility disorders induced by stress.
Compounds isolated from Gentianopsis barbata include 1-hydroxide-7-methoxyxanthene (Ping et al., 2003) and mangiferin (Luo et al., 2012). Mangiferin is a C-glucosylxanthone widely distributed in the Gentianaceae and is considered a key marker compound. Additionally, HPLC-MS profiling of related Gentianopsis species identified iridoid glycosides, flavones, and xanthones, with loganic acid, sweroside, loganin, secologanin, isoorientin-7-O-glucoside, luteolin-7-O-gentiobioside, chrysoeriol-7-O-glucoside, and acacetin-7-O-glucoside being present in the genus.
A major 2025 phytochemical investigation published in the Chinese Journal of Natural Medicines revealed a rich triterpenoid fraction in G. barbata. Fifty triterpenoids (1–50), including nine previously undescribed compounds, were isolated and characterised from whole plants of G. barbata. Notably, two of these compounds exhibited the novel 3,4;9,10-diseco-24-homo-cycloartane triterpenoid skeleton.
Comparative studies of Mongolian Gentiana species have shown that G. barbata exhibited the highest flavonoid content (33.4–38.6 rutin equivalents/g) among species examined. This relatively high polyphenol loading is consistent with the significant bioactivities documented in the species.
The most pharmacologically characterised mechanism for G. barbata xanthones is choleretic (bile-stimulating) activity. A study published in Eksperimental'naia i Klinicheskaia Farmakologiia (2003) directly investigated choleretic activity of isolated xanthone fractions from G. barbata. Comparative data were presented for the choleretic activity of xanthones isolated from Gentianopsis barbata (Froel.) Ma, comprising a sum of xanthone glycosides and aglycones, the xanthone aglycones decussatin and gentiacaulein, and the glycoside gentiabavaroside. It was established that xanthone aglycones are superior to the glycoside fraction with respect to cholagogic effect. This study is the primary direct evidence for bile-stimulating pharmacological activity specific to G. barbata, and was conducted in an experimental (animal/ex vivo) setting.
The isolated triterpenoids from G. barbata demonstrated substantial anti-inflammatory activity through inhibition of tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) cytokine secretion in LPS-induced RAW264.7 macrophages. TNF-α and IL-6 are central pro-inflammatory cytokines; their inhibition by LPS-stimulated macrophages in vitro is a widely used model for evaluating anti-inflammatory potential.
Triterpenoids from G. barbata demonstrated hepatoprotective effects by preventing tert-butyl hydroperoxide (t-BHP)-induced oxidative injury in HepG2 cells. The mechanism involves protection against oxidative stress in hepatocytes. Additionally, shared secoiridoid constituents (swertiamarin, gentiopicroside) found in G. barbata have broader mechanistic data from related Gentiana species: gentiopicroside, sweroside, and swertiamarin were responsible for hepatoprotective effects in Gentiana manshurica and Gentiana turkestanerum against carbon tetrachloride-induced hepatic damage in mice. These iridoids exerted hepatoprotective effects by diminishing oxidative stress in hepatocytes. In a rat liver damage model induced by α-naphthylisothiocyanate, swertiamarin at a dose of 20 mg/kg showed hepatoprotective effects by significantly reducing alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total and direct bilirubin levels, while conversely increasing bile flow.
The intensely bitter iridoids and secoiridoids in G. barbata interact with bitter taste receptors (TAS2Rs), which stimulate gastric acid secretion and bile production — the classical "bitter tonic" mechanism shared across the Gentianaceae. Gentian's primary therapeutic effects are linked to its ability to stimulate the production of gastric juices, digestive enzymes, and bile.
Evidence level: Preclinical (in vitro and in vivo animal studies); no published controlled human clinical trials identified specifically for G. barbata.
The most robust body of pharmacological data for G. barbata per se centres on liver-protective and bile-stimulating activity. The 2003 study by Nikolaev et al. in Eksperimental'naia i Klinicheskaia Farmakologiia (PMID 14558348) is the only published primary pharmacological study directly assessing isolated compounds from G. barbata: comparative data were presented for the choleretic activity of xanthones isolated from Gentianopsis barbata (Froel.) Ma, comprising xanthone glycosides and aglycones, including decussatin, gentiacaulein, and gentiabavaroside. Xanthone aglycones were superior to glycosides with respect to cholagogic effect. This is an in vivo pharmacological study in animals, providing mechanistic evidence for traditional use in liver/biliary disease, but it does not constitute clinical evidence in humans.
The 2025 study published in the Chinese Journal of Natural Medicines by Li et al. (DOI: 10.1016/S1875-5364(25)60870-3) contributes important in vitro data: fifty triterpenoids were isolated and characterised from whole plants of G. barbata, including nine previously undescribed compounds and two with a novel cycloartane triterpenoid skeleton. The isolated triterpenoids demonstrated substantial anti-inflammatory activity through inhibition of TNF-α and IL-6 in LPS-induced RAW264.7 macrophages, and hepatoprotective effects by preventing t-BHP-induced oxidative injury in HepG2 cells. These results demonstrate both the presence of diverse triterpenoids in G. barbata and their therapeutic potential for inflammatory and hepatic conditions, providing scientific evidence supporting the clinical application of this traditional Mongolian medicinal plant. This is in vitro evidence only; clinical translation has not been demonstrated.
At the level of Traditional Mongolian Medicine clinical usage, a study of 80 patients who underwent chemotherapy showed that the application of Mongolian medicine formulae in patients with hepatic injury is significantly effective, though this refers to multi-herb Mongolian formulae and cannot be attributed to G. barbata in isolation.
The hepatoprotective properties of key shared constituents (gentiopicroside, swertiamarin, sweroside) have further mechanistic support: gentiopicroside significantly reduced alpha-naphthylisothiocyanate-induced hepatic injury in rats by upregulating hepatic mRNA levels of synthesis enzymes (Cyp8b1 and Cyp27a1), transporters (Mrp4, Mdr1, and Ost-β), and ileal bile acid circulation mediators (Asbt and Fgf15). This mechanistic characterisation, while derived from work on Gentiana rigescens, is relevant to G. barbata given the shared constituent profile.
Related Gentianopsis species (G. komarovii, G. stricta) have also been investigated for choleretic activity: extracts of G. komarovii and G. stricta demonstrated choleretic potential, strengthening the bile flow and the total content of bile acids, bilirubin, and cholesterol in the bile, consistent with the reported activity of G. barbata xanthones.
Evidence level: Preclinical (in vitro cell culture); no human clinical trials identified.
Triterpenoids isolated from G. barbata demonstrated substantial anti-inflammatory activity through inhibition of TNF-α and IL-6 cytokine secretion in LPS-induced RAW264.7 macrophages. This in vitro finding is mechanistically meaningful but requires validation in animal models and ultimately in humans before clinical conclusions can be drawn.
Evidence level: Preliminary (comparative in vitro analyses); no species-specific clinical data.
Comparative phytochemical analyses of Mongolian gentian species recorded that G. barbata showed the highest flavonoid content (33.4–38.6 rutin equivalents/g) among studied species. High flavonoid and xanthone content correlates with radical-scavenging capacity in related species, though direct DPPH or ABTS antioxidant assays specifically for G. barbata have not been prominently reported in the peer-reviewed literature identified.
Studies suggest that naturally occurring xanthones exhibit a variety of in vitro and in vivo pharmacological activities which include hypoglycemic, antitumour, antioxidant, antihepatotoxic, CNS depressant, or stimulant effects. This applies to the xanthone chemical class broadly and is relevant to G. barbata given its documented xanthone content.
Evidence level: Plausible based on chemical constituents and family-level evidence; no clinical studies specific to G. barbata identified.
The bitter iridoids and secoiridoids present in G. barbata (gentiopicroside, swertiamarin) are shared with pharmacologically well-characterised species such as Gentiana lutea, where clinical evidence for digestive bitter activity exists. For G. barbata specifically, only traditional use records and the choleretic study support gastrointestinal indications. HPLC quantification of specific compounds in gentian herbs demonstrated high content of iridoids (24.73–73.53 mg/g) and flavonoids (12.92–78.14 mg/g), with decoctions showing good ability to stimulate acid and enzyme secretion. Although this study examined four Siberian Gentiana species, the chemical profile is comparable to G. barbata.
Evidence level: Limited; noted in comparative phytochemical analyses.
The bioactivities of plants from Gentianeae include antibacterial effects as documented in the broader family review. No antibacterial studies specific to G. barbata were found in peer-reviewed sources searched.
Based on verifiable traditional use records and preclinical pharmacological data, Gentianopsis barbata is associated with the following body systems and health areas:
There is currently no standardised dosage for Gentianopsis barbata established by any major regulatory body or pharmacopoeia in the Western world. The following dosage forms and quantities appear in the scientific and traditional literature:
No human clinical dose-finding or dose-ranging studies for Gentianopsis barbata as a standalone supplement have been identified in the peer-reviewed literature.
Formal safety data (toxicology studies, adverse event reporting, clinical safety trials) specific to Gentianopsis barbata are not available in the peer-reviewed sources identified. The following points are based on source-supported observations:
Gentianopsis is a small gentianaceous genus with a known ethnopharmacological focus as hepatoprotectors; several species remain scientifically underexplored. For G. barbata specifically, challenges of traditional Mongolian materia medica revitalisation include inheritors and sustainability concerns, elucidation of effective composition and pharmacology, and preparation and standardisation. The available scientific evidence is primarily restricted to phytochemical characterisation studies and in vitro pharmacological assays. There are no published randomised controlled trials, systematic reviews, or pharmacokinetic/pharmacodynamic studies in humans for G. barbata as an isolated supplement. The pharmacological data demonstrate both the presence of diverse triterpenoids in G. barbata and their therapeutic potential for inflammatory and hepatic conditions, providing scientific evidence supporting the clinical application of this traditional Mongolian medicinal plant — but translational evidence from human studies is still absent.
Health conditions that Gentianopsis barbata may help support.
Body systems that Gentianopsis barbata may help support.
Go back